

19 July 2022

## Cancer Pharma

**Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:**

- Avelumab + Axitinib: 8
- Axinitib
- Cabozantinib: 22
- Everolimus
- Lenvatinib + Everolimus
- Nivolumab: 26
- Nivolumab + Cabozantinib
- Nivolumab + Ipilimumab: 7
- Pazopanib: < 5
- Pembrolizumab monotherapy
- Pembrolizumab + Axitinib
- Pembrolizumab + Lenvatinib
- Sunitinib: 9
- Temsirolimus
- Tivozanib: 12
- Other active systemic anti-cancer therapy

Please note:

- Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

**Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):**

- Cobimetinib
- Dabrafenib: < 5
- Dabrafenib AND Trametinib: 20
- Dacarbazine
- Encorafenib AND Binimetinib: 30
- Ipilimumab
- Ipilimumab AND Nivolumab: 8
- Nivolumab: 10
- Pembrolizumab: 41
- Trametinib
- Vemurafenib
- Vemurafenib AND Cobimetinib

19 July 2022

- Other active systemic anti-cancer therapy:  
 Levantinib&Pembro: < 5  
 Tebentafusp MAP: < 5
- Palliative care only

**Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:**

- Cobimetinib
- Dabrafenib
- Dabrafenib AND Trametinib
- Encorafenib AND Binimetinib
- Ipilimumab
- Ipilimumab AND Nivolumab
- Nivolumab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib AND Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only

Response: We are unable to distinguish if disease is metastatic

**Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?**

Belfast Trust Nephrectomy Numbers

Period of Report: 1st January to 31st March 2022 (Latest figures held)

Operation	Total
M02.1	< 5
M02.2	< 5
M02.5	11
M03.9	16
M10.4	13

Source: BOXI

Produced by Information Services Department, version (VER1) 15/07/22